Boston Scientific Corporation announced that data from a randomized clinical trial demonstrate that Rezum™ Water Vapor Therapy, a minimally invasive treatment for benign prostatic hyperplasia (BPH), provides durable results and preserves sexual function four years after treatment. The study, published online ahead of print by Urology, found that patients continued to experience significant and sustained improvement in their symptoms and quality of life over this period. BPH, which affects 110 million men worldwide, is an enlargement of the prostate in which prostate adenoma cells form excess tissue that may cause symptoms, which impact a patient's quality of life, such as a frequent and urgent need to urinate. The Rezum System treats the symptoms of BPH by using water vapor to kill prostate adenoma cells, leading to the cell remnants being absorbed by the body. The procedure can be performed in a physician's office without general anesthesia in a single visit and does not require implants to be placed in the body. The Rezum System is included in The American Urological Association's BPH treatment guidelines and now has four-year follow-up data showing it can reduce the size of the prostate in all areas of enlarged prostate zones. Over the four years, the trial showed a surgical retreatment rate of 4.4% and no new adverse events noted between years three and four. The clinical results also highlighted continued preservation of sexual function, including no de novo erectile dysfunction reported at four years.